Treating patients based on the presence of molecular abnormalities regardless of tumor type proved to be a promising strategy in an ongoing phase 2a basket study. An ongoing phase 2a study is proving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback